Compare Stocks → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:HOOKNASDAQ:IMNMNASDAQ:ONCTNASDAQ:ORPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHookipa Pharma$0.77-3.8%$0.78$0.41▼$2.05$75.99M0.92738,167 shs623,570 shsIMNMImmunome$15.50+0.1%$20.36$4.50▼$30.96$929.07M1.87729,790 shs1.05 million shsONCTOncternal Therapeutics$8.80+2.0%$8.73$5.57▼$13.14$26.05M1.2811,046 shs2,568 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHookipa Pharma0.00%-12.84%-4.92%+18.24%-56.99%IMNMImmunome-1.40%+3.41%-24.41%-33.02%+145.71%ONCTOncternal Therapeutics+1.84%+1.32%+2.43%-6.93%+43.92%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOOKHookipa Pharma2.0441 of 5 stars3.53.00.00.00.01.71.3IMNMImmunome1.8021 of 5 stars3.50.00.00.03.21.70.0ONCTOncternal Therapeutics3.2849 of 5 stars3.35.00.00.02.41.71.3ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOOKHookipa Pharma3.00Buy$4.67507.64% UpsideIMNMImmunome3.00Buy$30.5096.77% UpsideONCTOncternal Therapeutics2.67Moderate Buy$31.33256.06% UpsideORPHOrphazyme A/SN/AN/AN/AN/ACurrent Analyst RatingsLatest HOOK, ONCT, ORPH, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2024IMNMImmunomeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$24.004/26/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.50 ➝ $5.004/15/2024IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/15/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.004/1/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $33.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.50(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOOKHookipa Pharma$20.13M3.78N/AN/A$0.91 per share0.84IMNMImmunome$14.02M66.27N/AN/A$2.77 per share5.60ONCTOncternal Therapeutics$790K32.97N/AN/A$10.19 per share0.86ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%8/8/2024 (Estimated)IMNMImmunome-$106.81M-$5.39N/AN/AN/A-761.92%-69.74%-31.40%5/10/2024 (Estimated)ONCTOncternal Therapeutics-$39.48M-$13.51N/AN/AN/A-5,029.17%-95.87%-83.56%8/8/2024 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ALatest HOOK, ONCT, ORPH, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024HOOKHookipa Pharma-$0.12$0.12+$0.24$0.13$3.20 million$36.60 million5/9/2024Q1 2024ONCTOncternal Therapeutics-$2.88-$2.83+$0.05-$2.83$0.18 million$0.57 million 3/28/2024Q4 2023IMNMImmunome-$0.28-$0.54-$0.26$3.14$3.40 million$3.83 million3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/7/2024Q4 2023ONCTOncternal Therapeutics-$3.09-$3.11-$0.02-$3.11$0.17 million$0.30 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOOKHookipa PharmaN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOOKHookipa PharmaN/A3.503.50IMNMImmunomeN/A6.636.63ONCTOncternal TherapeuticsN/A6.946.94ORPHOrphazyme A/S0.141.80N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOOKHookipa Pharma63.88%IMNMImmunome44.58%ONCTOncternal Therapeutics16.05%ORPHOrphazyme A/S10.74%Insider OwnershipCompanyInsider OwnershipHOOKHookipa Pharma5.82%IMNMImmunome20.00%ONCTOncternal Therapeutics8.00%ORPHOrphazyme A/SN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHOOKHookipa Pharma5698.95 million94.40 millionOptionableIMNMImmunome5559.94 million47.95 millionOptionableONCTOncternal Therapeutics272.96 million2.72 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableHOOK, ONCT, ORPH, and IMNM HeadlinesSourceHeadlineSome Alzheimer's cases may be caused by copies of a single gene, research showsfoxnews.com - May 7 at 9:51 PMStudy Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snytimes.com - May 7 at 1:50 AMA gene long thought to just raise the risk for Alzheimer's may cause some casesabcnews.go.com - May 7 at 1:50 AMA subset of Alzheimer’s cases may be caused by two copies of a single gene, new research showsorlandosentinel.com - May 6 at 8:49 PMGenes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers saymsn.com - May 6 at 8:49 PMScientists may have found a way to make a universal donor bloodmsn.com - May 6 at 1:17 AMAllozymes puts its accelerated enzymatics to work on a data and AI play, raising $15Myahoo.com - May 3 at 9:53 PMBiomarker test to ID Alzheimer’s wins FDA breakthrough designationalzheimersnewstoday.com - May 3 at 2:31 AMRapamycin shows promise in slowing Alzheimer's disease progression linked to seizuresmsn.com - May 2 at 1:15 PMOrgan transplant drug may slow Alzheimer's disease progressionmsn.com - May 1 at 5:13 PMFTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA databasefiercepharma.com - May 1 at 5:13 PMNeurocrine Biosciences’ Huntington’s disease drug gets FDA approvalkfgo.com - April 30 at 9:11 PMOrisa, Venture hit with nerfs in Overwatch 2’s latest balance patchdotesports.com - April 30 at 4:11 PMStrategic Innovation in SARMs: OTR-AC's Esterification Advantagemsn.com - April 30 at 4:11 PMEnlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Groupbiospace.com - April 30 at 11:11 AMOrpheus Pledger was on SAS Australia for a 'redemption arc'. Now there's been a manhunt for him.msn.com - April 27 at 5:36 AMAnopheles stephensi Mosquitoes: An Old Problem, A New Threat to Malaria Mitigationwilsoncenter.org - April 26 at 2:41 AMPhase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patientsmsn.com - April 20 at 10:46 AMOlympic torch makes Acropolis overnight stop a week before handover to Paris organizersmsn.com - April 19 at 6:28 PMSyphilis cases in Colorado are exploding. The state just issued a public health order to try to stop that.coloradosun.com - April 19 at 6:28 PMInside Gen Alpha’s controversial obsession with skincarenbcnews.com - April 18 at 3:22 PMIt’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?msn.com - April 13 at 11:29 AMLysine Is Important for the Body, and Is Generally a Safe Supplementmsn.com - April 12 at 12:36 PMSTALICLA Appoints Dr. Thomas Blaettler, MDalbawaba.com - April 12 at 2:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.ImmunomeNASDAQ:IMNMImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Oncternal TherapeuticsNASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Orphazyme A/SNASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.